8 Sep 2016
Notice of Interim Results

London, UK – 7 September 2016: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, will announce its interim results for the six months ended 30 June 2016 on Monday 26 September 2016.

A meeting for analysts will be held at 9:00am on 26 September 2016 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD.

Enquiries:

Ergomed plc                                                                                       Tel: +44 (0) 1483 503205

Miroslav Reljanovic (Chief Executive Officer)

Stephen Stamp (Chief Financial Officer)

Numis Securities Limited                                                             Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

Stifel Nicolaus Europe Limited                                                  Tel: +44 (0) 20 7710 7600

Jonathan Senior (Joint Broker)

FTI Consulting – for UK enquiries                                             Tel: +44 (0) 20 3727 1000          

Simon Conway / Mo Noonan

MC Services AG – for Continental European enquiries  Tel: +49 (0) 211 52925222

Anne Hennecke

About Ergomed

 

Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: https://ergomedplc.com.